Martin is a Chartered Patent Attorney and European Patent Attorney. He qualified as a Patent Attorney in 1999, joined Mathys & Squire in the same year, and became a Partner of the firm in 2004. Martin has a strong background in biochemistry and biotechnology, having obtained a first degree (Warwick University) in microbial technology and a PhD (Warwick University) for research conducted into the biochemical aspects of acidophilic bacteria. He also has a Masters Degree in IP from London University. 

Martin specializes in technologies such as the re-targeting of bacterial toxins, vaccines, expression systems, microbial detection assays, and cytokine-based therapeutics, and represents clients ranging from UK government and blue chip biotech companies through to spin-outs and start-ups. Martin’s principal practice areas include drafting and global prosecution, defence and opposition, freedom-to-operate, and strategic advice. In this regard, Martin has extensive experience in the conduct of Hearings before the European Patent Office, having conducted in excess of 30 Hearings – examples include “HIV peptides” (Adaltis, Abbott Lab, United Biomedical, Institut Pasteur, Bio-Rad Pasteur), “Factor XIII” (Novo Nordisk, Baxter, Aventis Behring), “TACI” (ZymoGenetics, Corixa, HGS), and “Omega-3” (Martek Biosciences, Nagase Biochem, Aventis R&T, OmegaTech, Monsanto).

Martin’s principal clients include ZymoGenetics Inc, Syntaxin Ltd, Health Protection Agency, Wellstat Biologics/Therapeutics, and The Cystic Fibrosis Trust.

In addition to the above professional activities, Martin acts as a tutor for the UK and European Qualifying Examinations, and regularly serves as a lecturer and clinician for the Chartered Institute of Patent Attorneys.